Percutaneous microwave ablation and transcatheter arterial chemoembolization for serum tumor markers and prognostics of middle-late primary hepatic carcinoma Authors: Zhi-Peng Lin, Da-Bei Huang, Xu-Gong Zou, Yuan Chen, Xiao-Qun Li, Jian Zhang Published: 2023 ABSTRACT AbstractBACKGROUNDPrimary hepatic carcinoma (PHC) has an insidious onset and is usually diagnosed in the middle and late stages. Although transcatheter arterial chemoembolization (TACE) is the preferred option for treating middle- and advanced-stage PHC, it has limited efficacy in killing tumor cells and poor long-term efficacy. TACE plus percutaneous microwave coagulation therapy (PMCT) is more effective than interventional therapy alone and can improve survival time. However, there are few reports on the effects of TACE and PMCT on serum marker levels and the prognosis of patients with advanced PHC.AIMTo investigate the effect of PMCT + TACE on serum tumor markers and the prognosis of middle-late PHC.METHODSThis retrospective study included 150 patients with middle-late PHC admitted to Zhongshan People’s Hospital between March 2018 and February 2021. Patients were divided into a single group (treated with TACE, n = 75) and a combined group (treated with TACE + PMCT, n = 75). Before and after treatment, the clinical efficacy and serum tumor marker levels [carbohydrate antigen 19-9 (CA19-9), alpha-fetoprotein (AFP), and carcinoembryonic antigen (CEA)] of both groups were observed. The 1-year survival rates and prognostic factors of the two groups were analyzed.RESULTSThe combined group had 21 and 35 cases of complete remission (CR) and partial remission (PR), respectively. The single group had 13 and 25 cases of CR and PR, respectively. After 4 wk of treatment, the serum CA19-9, CEA, and AFP levels in the single and combined groups decreased, with the decrease in the combined group being more significant (P < 0.05). The 1-year survival rate of the combined group (80.00%) was higher than that of the single group (60.00%) (P < 0.05). The average survival time within 1 year in the combined group was 299.38 ± 61.13 d, longer than that in the single group (214.41 ± 72.97 d, P < 0.05). COX analysis revealed that tumor diameter, tumor number, and the treatment method were prognostic factors for patients with middle-late PHC (P < 0.05).CONCLUSIONTACE + PMCT is effective in treating patients with mid-late PHC. It reduces the levels of tumor markers, prolongs survival, and improves prognosis.Keywords: Middle-late primary hepatic carcinoma, Percutaneous microwave coagulation therapy, Transcatheter arterial chemoembolization, Effect, Tumor markers, Prognosis, Survival Core Tip: Middle- and late-stage primary hepatic carcinoma (PHC) has reached a phase of comprehensive treatment. Compared to single interventional therapy, transcatheter arterial chemoembolization (TACE) plus percutaneous microwave coagulation therapy (PMCT) can effectively improve prognosis and prolong patient survival. This study reveals that TACE + PMCT in the management of patients with middle-late PHC enhances tumor marker levels and prolongs survival time. Furthermore, we identify tumor diameter, tumor number, and treatment method as pivotal factors influencing prognosis. INTRODUCTION Primary hepatic carcinoma (PHC) is a common histological form of liver cancer, accounting for 70.0%–85.0% of total liver cancer cases, with a markedly poor prognosis[1]. Currently, the primary treatment methods for PHC include radical surgical resection, targeted therapy (such as sorafenib, lenvatinib, cabozantinib, etc.), interventional and immunotherapy[2]. Surgical resection can achieve significant efficacy in early PHC cases; however, due to the hidden onset of the disease, that is, the absence of obvious symptoms and signs in the early stages, only 20%–30% of patients undergo surgical resection in the middle to late stages[3]. Interventional therapy is the primary option for middle-aged patients who miss the optimal surgery window[4]. Transcatheter arterial chemoembolization (TACE) is a common type of interventional therapy for patients with middle-to-late stage PHC[5]. Normally, the liver receives blood supply through two routes: the portal vein supplies 70%–75%, and the hepatic artery supplies 20%–25%. However, the liver cancer tissue supplies 90%–95% of the latter[6]. TACE takes advantage of these features. On the one hand, embolization is performed on the target artery supplying blood to the tumor, resulting in tumor shrinkage and ischemic necrosis. On the other hand, it selectively injects chemotherapy drugs into the target lesion, thus achieving the goal of treating PHC with minimal damage to normal liver tissue[7,8]. However, TACE cannot completely eliminate the target lesion and is prone to tumor recurrence. The above drawbacks are major factors for patients undergoing multiple treatments and adjusting their treatment plans[9]. With the continuous development of new hyperthermia technologies, studies have shown that TACE plus percutaneous microwave coagulation therapy (PMCT) can improve the clinical curative effect in patients with liver cancer and prolong survival time[10,11]. In addition, PMCT can effectively improve anti-tumor immune responses in the body[12]. However, there are few reports on the effects of TACE and PMCT on serum marker levels and the prognosis of patients with advanced PHC. This study retrospectively analyzed the effects of PMCT combined with TACE on serum tumor marker levels and prognosis in patients with mid-late PHC to provide a reference for clinical management. MATERIALS AND METHODS Object This study involved 150 patients with mid-late PHC admitted to Zhongshan People’s Hospital between March 2018 and February 2021. The inclusion criteria were as follows: (1) PHC diagnosis confirmed by medical imaging, serum tumor marker detection, and pathological test; (2) Tumor TNM stage Ⅱ–IV, with no indication for surgery or surgery cannot be performed; and (3) Complete clinical data and follow-up information. The exclusion criteria were as follows: (1) Significant organ dysfunction (such as kidney, heart, lung, etc.) or severe illnesses; (2) combined with coagulation dysfunction; (3) Contraindications to TACE and PMCT; (4) Presence of other malignant tumors; (5) History of past PMCT or TACE treatment; (6) Recurrence of lung cancer; and (7) Patients with mental illness and inability to cooperate. Based on the different treatments, the patients were separated into a single group (n = 75) and a combined group (n = 75). No statistically significant differences were observed in the basic data between the single and combined groups (P > 0.05), as shown in Table 1. Table 1Comparison of baseline data between the single and combined groups Group Gender Age (yr) Tumor number (cases) Tumor diameter (cm) Male Female Single Multiple Combined group (n = 75)41 (54.67)34 (45.33)53.05 ± 13.4347 (62.67)28 (37.33)5.11 ± 1.27Single group (n = 75)43 (57.33)32 (42.67)52.51 ± 12.0649 (65.33)26 (34.67)5.49 ± 1.23 χ2/t value0.108-0.5580.262-1.900 P value0.7420.5800.7930.059 Comparison of baseline data between the single and combined groups Methods The single group was treated under local anesthesia with TACE alone, guided by digital subtraction angiography, and percutaneous puncture of the femoral artery to the mesentery and the common hepatic artery. The catheter was placed into the main supplying artery of the lesion, and oxaliplatin (100 mg) and liquefied iodide (10 mL) were injected through the catheter. The main feeding artery was embolized with a gelatin sponge particle, and the effect of the embolization was again observed on angiography. Depending on the patient's condition before and after the first TACE treatment, the treatment was repeated 1 to 3 times, and the interval between the two TACE treatments was not less than 4 wk. The combined group underwent a treatment regimen involving TACE + PMCT. Specifically, this group received 1–2 rounds of TACE treatment followed by 2–4 wk of combined PMCT treatment. In contrast, the single group received only TACE treatment. Before initiating microwave ablation (MWA) treatment, imaging studies were conducted on all patients to select the needle entry path. Special care was taken to minimize the risk of puncturing important organs such as the gallbladder, large blood vessels, and gastrointestinal tract. First, preoperative preparation for conventional MWA was performed. Guided by a spiral CT scan, 1–2 MWA needles were inserted percutaneously into the tumor tissue, and a combined multisite ablation was performed by adjusting the depth and angle of the microwave antenna. The ablation power and time were selected according to the patient's lesion size and tolerance, as well as surrounding organs at risk. Postoperatively, the two groups of patients were treated with liver-protective, antiemetic, and antipyretic agents. Imaging studies were performed in both groups 2–4 wk after surgery, and the therapeutic effect was evaluated. Survey tools Clinical efficacy: Four weeks after the last treatment, the clinical efficacy in the enrolled patients was evaluated according to the mRECIST (modified response evaluation criteria in solid tumors) evaluation criteria[13]. Complete remission (CR) was defined as complete tumor disappearance sustained for at least 4 wk. Partial remission (PR) was defined as tumor shrinkage ≥ 30%, sustained for at least 4 wk. The tumor: Stable with a reduction of < 30% or an increase but an increase of < 20%; Disease progression was characterized by tumor enlargement ≥ 25%, new tumors, or metastatic lesions. Objective response rate (ORR) = (PR + CR) cases/total cases × 100%. Serum tumor markers: Precisely, 5.0 mL of venous blood was collected from the enrolled patients before treatment and 4 wk after treatment. The serum of the collected blood was separated using centrifugation and stored in a specially insulated refrigerator for drugs at 2–6℃. The serum levels of carbohydrate antigen 19-9 (CA19-9), alpha-fetoprotein (AFP), and carcinoembryonic antigen (CEA) in the two groups were measured using an i2000 automatic microparticle chemiluminescence immunoanalyzer (Abbott Laboratories, United States). Survival: The patients were followed up for 1 year after treatment (until January 2022). The recurrence, metastasis, and death rates in the single and combined groups were recorded, and prognostic factors related to the patients with mid-late PHC were analyzed. Statistical analysis Data were analyzed using IBM SPSS software (version 26.0). Counting variables are expressed as [n (%)], and continuous variables are reported as mean ± SD. These variables were tested using t-tests (also known as Student's t test) and χ2 tests, respectively. The survival rate was analyzed using the Kaplan–Meier method, while prognostic factors were assessed using the COX method. Inspection level as the α = 0.05. Statistical significance was set at P < 0.05. RESULTS Clinical effect The combined group had 21 and 35 cases of CR and PR, respectively. The single group had 13 and 24 cases of CR and PR, respectively. The ORR of the combined group was higher (74.67%, P < 0.05) than that of the single group (49.33%), as shown in Table 2. Table 2Comparison of clinical efficacy between the single and combined groups Group CR PR SD PD ORR (%) Combined group (n = 75)21 (28.00)35 (46.67)15 (20.00)4 (5.33)56 (74.67)1Single group (n = 75)13 (17.33)24 (32.00)28 (37.33)10 (13.33)38 (49.33)χ2 value9.233 P value0.0021 P < 0.01 vs single group.CR: Complete remission; PR: Partial remission; SD: Stable; PD: Disease progression; ORR: Objective response rate. Comparison of clinical efficacy between the single and combined groups P < 0.01 vs single group. CR: Complete remission; PR: Partial remission; SD: Stable; PD: Disease progression; ORR: Objective response rate. Serum tumor marker levels Before treatment, the levels of serum tumor markers in the single and combined groups were compared (all P > 0.05). After 4 wk of treatment, the serum CA19-9, CEA, and AFP levels in the single and combined groups decreased. The decrease in the combined group was more significant (P < 0.05) (Table 3). Table 3Comparison of serum tumor marker levels between the two groups before treatment and 4 wk after treatment Group AFP (g/L) CEA (g/mg) CA19-9 (U/mL) Pre-treatment After 4 wk of treatment Pre-treatment After 4 wk of treatment Pre-treatment After 4 wk of treatment Combined group (n = 75)364.17 ± 50.46212.52 ± 39.52219.44 ± 2.0511.02 ± 2.182239.87 ± 40.16170.25 ± 28.281Single group (n = 75)361.74 ± 51.78256.23 ± 42.1119.32 ± 2.1113.56 ± 2.40240.56 ± 40.22189.54 ± 38.84 t value-0.290-6.5530.325-6.770-0.105-3.477 P value0.772< 0.0010.746< 0.0010.9160.0011 P < 0.01 vs single group.2 P < 0.001 vs single group.AFP: Alpha-fetoprotein; CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen 19-9. Comparison of serum tumor marker levels between the two groups before treatment and 4 wk after treatment P < 0.01 vs single group. P < 0.001 vs single group. AFP: Alpha-fetoprotein; CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen 19-9. Survival after 1 year By the end of the follow-up period, the recurrence and metastasis rates in both the combined and single groups yielded P values greater than 0.05. The 1-year survival rate was significantly higher in the combined group (80.00%) compared to the single group (60.00%, P < 0.05), as shown in Table 4. Additionally, the average survival time in the combined group (299.38 ± 61.13 d) was longer than that in the single group (214.41 ± 72.97 d, P < 0.05, Figure 1). Table 4Comparison of survival after 1 year between the single and combined groups Group Recrudescence Transfer Death Combined group (n = 75)22 (29.33)5 (6.67)16 (21.33)1Single group (n = 75)32 (42.67)10 (13.33)30 (40.00) χ2 value 2.8941.8526.145 P value0.0890.1740.0131 P < 0.05 vs single group. Comparison of survival after 1 year between the single and combined groups P < 0.05 vs single group. Survival curves for the single and combined groups. The survival rate of the two groups was compared by log-rank test. The survival rate of the single group was significantly lower than that of the combined group (log-rank χ2 = 7.503, P = 0.006). Analysis of factors influencing prognosis in patients with mid-late PHC The patients were divided into survival (n = 104) and death (n = 46) groups. Univariate analysis indicated a significant relationship between prognosis and tumor diameter, tumor number, and treatment method (P < 0.05), as shown in Table 5. Table 5Univariate analysis affecting the prognosis of patients with mid-late PHC Item Death group (n = 46) Survival group (n = 104) χ2 P value Gender (male/female)21/2563/412.8830.090Age (yr)0.4030.836 ≥ 6016 (34.78)38 (36.54) < 6030 (65.22)66 (63.46)Tumor diameter (cm)17.559< 0.0012 ≥ 631 (67.39)32 (30.77) < 615 (32.61)72 (69.23)Tumor number (cases)23.588< 0.0012 Single17 (36.96)81 (77.88) Multiple29 (63.04)23 (22.12)Treatment method (cases)6.1450.0131 Single TACE30 (65.22)45 (43.27) TACE + PMCT16 (34.78)59 (56.73)1 P < 0.05.2 P < 0.0001.TACE: Transcatheter arterial chemoembolization; PMCT: Percutaneous microwave coagulation therapy. Univariate analysis affecting the prognosis of patients with mid-late PHC P < 0.05. P < 0.0001. TACE: Transcatheter arterial chemoembolization; PMCT: Percutaneous microwave coagulation therapy. Cox analysis of factors influencing prognosis of patients with mid-late PHC The COX proportional risk model was used to analyze and assign the study variables (Table 6). The results showed that the factors influencing the prognosis of patients with middle and advanced PHC were tumor diameter, tumor number, and treatment methods (P < 0.05, Table 7). Table 6Specific values Variable GenderMale = 1, female = 0Age≥ 60 yr = 1, < 60 yr = 0Tumor diameter≥ 6 cm =1, < 6 cm = 0Tumor numberSingle = 1, Multiple = 0Treatment methodSingle TACE = 1, TACE + PMCT = 0TACE: Transcatheter arterial chemoembolization; PMCT: Percutaneous microwave coagulation therapy. Specific values TACE: Transcatheter arterial chemoembolization; PMCT: Percutaneous microwave coagulation therapy. Table 7Cox analysis of effects of various factors on the prognosis of patients with mid-late primary hepatic carcinoma Item B SE Wald P value OR 95%CI Tumor diameter0.9890.3398.4950.0042.6891.383-5.230Tumor number1.0760.33010.6590.0012.9341.537-5.598Treatment method1.0060.3299.3360.0021.7351.434-5.21595%CI: 95% confidence interval; OR: Odds ratio. Cox analysis of effects of various factors on the prognosis of patients with mid-late primary hepatic carcinoma 95%CI: 95% confidence interval; OR: Odds ratio. DISCUSSION Owing to the hidden onset and rapid progression of PHC, most patients are diagnosed at the mid-late stage, and the opportunity for surgery is lost. Local intervention, thermal ablation, and chemotherapy have become primary treatments. As the preferred treatment for middle-late PHC, TACE can achieve a 1-year survival rate of more than 80%[14]. However, it has been reported in relevant literature that TACE treatment cannot improve the survival rate of patients with tumor diameter > 5 cm, and that the local hypoxia caused by a single TACE treatment may promote the regeneration of tumor blood vessels, resulting in high recurrence and metastasis rates for advanced liver cancer[15,16]. Therefore, combining TACE therapy with other treatment options has become the consensus for treating patients with PHC, especially those with mid-late disease who cannot be treated with surgery[17]. PMCT is a commonly used thermal ablation therapy for tumors. The basic principle is that the polar molecules within a substance can vibrate violently under the action of a rapidly changing electromagnetic field, generating a large amount of heat. Cancer cells stop proliferating when the lesion site is heated to an appropriate temperature, and tumor tissues begin to coagulate and necrose[12,18]. Studies have shown that PMCT has good clinical value because it offers advantages such as a good anti-heat sink effect, a wide MWA range, rapid local lesion warming, short surgical operation time, and no intraoperative current generation[19]. In addition, TACE can induce ischemia and hypoxia in tumor tissues, enhance thermal sensitivity, and enhance the high-temperature killing effect of PMCT on tumor cells[20]. Li et al[21] recently published a study in patients with hepatocellular carcinoma (HCC) treated with TACE combined with MWA, which showed that the CR of TACE + MWA was higher compared to TACE alone, (65% vs 46%). Simultaneously, progression-free survival was significantly prolonged in the TACE + MWA treatment group (29 vs 19 mo), and conventional TACE + MWA did not increase the risk of adverse events. A meta-analysis by Wang et al[22] showed that the survival of patients treated with TACE + MWA was significantly better than that of patients treated with TACE alone, especially in patients with tumor diameters > 5 cm. This study found that, compared to the single group, the combined group had a higher CR (28% vs 17.33%) and a higher ORR (74.67% vs 50.67%). After 1 year of follow-up, there were no statistically significant differences in the recurrence and metastasis rates between the combined and single groups (P > 0.05). The survival rate in the combined group (80.00%) was higher than that in the single group. The average survival time of the combined group (299.38 ± 61.13 d) was longer than that of the single group (214.41 ± 72.97 d). These results suggest that TACE combined with PMCT can effectively treat middle-late PHC and improve patient survival rates. Tumor markers are important indicators of tumor progression and are related to biological behaviors. As a new type of digestive system-specific antigen, CEA can comprehensively reflect the growth and ablation of malignant tumor cells[23,24]. AFP is a protein produced by embryonic stem cells and is mainly derived from undifferentiated hepatocytes and the fetal yolk sac. Related studies have reported that more than 70% of TACE patients have elevated serum AFP levels, and the more severe the patient's condition, the higher the serum AFP level[25,26]. CA19-9 is an oligosaccharide antigen secreted by digestive tract tumor cells, and its expression is upregulated in patients with liver cancer[27]. This study found that after 4 wk of treatment, the serum levels of CA19-9, AFP, and CEA in the single and combined groups decreased. However, the decrease was more obvious in the combined group, suggesting that combining TACE with PMCT can effectively reduce serum levels of CA19-9, AFP, and CEA in patients with advanced PHC. This study further explored the factors affecting the prognosis of patients with middle-late PHC. We found that tumor diameter, tumor number, and treatment method (P < 0.05) are factors affecting the prognosis of patients with middle-late PHC. The rationale behind this analysis is that large tumors are not easily inactivated as a whole during treatment, which can easily cause residual tumors and recurrence. In addition, patients with large tumors have a low liver reserve compensatory function, which can easily cause liver failure and death during treatment[28,29]. The number of tumors predicts the degree of intrahepatic spread; the higher the number of tumors, the higher the chance of recurrence[30]. This study proved that the combination of TACE and PMCT can improve patient prognosis. This was a retrospective study, which was limited by the sample size and follow-up time. Therefore, to further demonstrate the role of combination therapy in patients with mid-late PHC, prospective randomized controlled studies of this nature should be conducted. CONCLUSION TACE + PMCT has good clinical efficacy in the treatment of patients with middle-late PHC and can effectively improve the survival rate of these patients. Tumor diameter, tumor number, and treatment methods are factors associated with the prognosis of patients with middle-late PHC. ARTICLE HIGHLIGHTS Research background Patients with middle-late primary hepatic carcinoma (PHC) exhibit distinct characteristics, such as large tumors, multiple tumor lesions, and satellite lesions. Achieving a good embolization effect after multiple transcatheter arterial chemoembolization (TACE) treatments can often be challenging. percutaneous microwave coagulation therapy (PMCT) can accurately reach the tumor site, heat the tumor locally, and cause coagulation necrosis. Currently, TACE plus PMCT is more effective than interventional therapy alone and can improve survival time. However, there are few reports on the effects of TACE and PMCT on serum markers and the prognosis of patients with advanced PHC. Research motivation Compared to single TACE therapy, TACE + PMCT has a better effect in clinical applications. However, most studies have focused on efficacy and safety, and there are few reports on the factors affecting the prognosis of patients with middle-late PHC and the improvement of tumor markers in patients treated with TACE + PMCT. Research objectives To explore the effect of TACE + PMCT on tumor markers and prognosis in patients with mid-late PHC. Research methods Patients were divided into a single group (TACE treatment) and a combination group (TACE + PMCT treatment), according to the treatment methods. Serum tumor markers [alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9)] and the clinical efficacy of the single and combined groups were observed before treatment and 4 wk after treatment. The 1-year survival rates and prognostic factors of the two groups were analyzed. Research results The objective response rate in the combined group was 74.67%, higher than that in the single group (50.67%) (P < 0.05). After 4 wk of treatment, the serum AFP, CEA, and CA19-9 Levels in the single and combined groups decreased, with the decrease in the combined group being more significant (P < 0.05). The 1-year survival rate at the end of the follow-up period was 80.00% in the combined group and 60.00% in the single group (P < 0.05). The average survival time in the combined group was 299.38 ± 61.13 days, longer than that in the single group (214.41 ± 72.97 d, P < 0.05). COX analysis revealed the effect of tumor diameter, the number of tumors, and the treatment method on the prognosis of patients with middle-to-the newest PHC (P < 0.05). Research conclusions TACE + PMCT has good clinical efficacy in the treatment of mid-late PHC and can effectively improve the survival rate of patients. Tumor diameter, number, and treatment method were related to the prognosis of patients with mid-late PHC. Research perspectives This study provides a reference for the clinical management of patients with mid-late PHC. Footnotes Institutional review board statement: The study was reviewed and approved by the Zhongshan People’s Hospital Institutional Review Board (Approval No. 2023-038). Informed consent statement: This is a retrospective study article, which selected anonymous patients from the hospital system. The patient's identity information was not disclosed and will not cause any harm to the patient. An application for exemption from informed consent has been made to the ethics committee. Conflict-of-interest statement: The authors declare no conflicts of interest for this article. Provenance and peer review: Unsolicited article; Externally peer reviewed. Peer-review model: Single blind Peer-review started: October 26, 2023 First decision: November 8, 2023 Article in press: December 4, 2023 Specialty type: Gastroenterology and hepatology Country/Territory of origin: China Peer-review report’s scientific quality classification Grade A (Excellent): 0 Grade B (Very good): 0 Grade C (Good): C, C Grade D (Fair): 0 Grade E (Poor): 0 P-Reviewer: Nozaki Y, Japan; Takehara T, Japan S-Editor: Lin C L-Editor: A P-Editor: Lin C Contributor Information Zhi-Peng Lin, Department of Interventional Medicine, Zhongshan People’s Hospital, Zhongshan 528400, Guangdong Province, China. Da-Bei Huang, Department of Interventional Medicine, Zhongshan People’s Hospital, Zhongshan 528400, Guangdong Province, China. Xu-Gong Zou, Department of Interventional Medicine, Zhongshan People’s Hospital, Zhongshan 528400, Guangdong Province, China. Yuan Chen, Department of Interventional Medicine, Zhongshan People’s Hospital, Zhongshan 528400, Guangdong Province, China. Xiao-Qun Li, Department of Interventional Medicine, Zhongshan People’s Hospital, Zhongshan 528400, Guangdong Province, China. Jian Zhang, Department of Interventional Medicine, Zhongshan People’s Hospital, Zhongshan 528400, Guangdong Province, China. wy18988583838@163.com. Data sharing statement Clinical data used in this study can be obtained from the corresponding author. References Associated Data Data Availability Statement Clinical data used in this study can be obtained from the corresponding author.